Long COVID - metabolic risk factors and novel therapeutic management

Cardiometabolic conditions, including type 1 and type 2 diabetes mellitus, are associated with severe COVID-19 and long COVID. Interventions to target multiple risk factors, combined with use of novel glucose-lowering agents that improve metabolic function and the key processes that are impaired in COVID-19, should be the preferred therapeutic options for management of people with long COVID.

Automated summary

Cardiometabolic conditions, like type 1 and type 2 diabetes mellitus, are linked to severe COVID-19 and long COVID. Interventions targeting multiple risk factors, along with the use of novel glucose-lowering agents, are recommended for managing long COVID in people.